

To be presented at the 6th Annual General Meeting  
of Marinomed Biotech AG  
on June 21, 2023

**Declaration according to Sec. 87 Para. 2 Stock Corporation Act [AktG]**

In accordance with Sec. 87 Para. 2 Stock Corporation Act, each person proposed for election to the Supervisory Board has to explain to the Annual General Meeting their expertise, their professional or comparable roles as well as all circumstances that could give cause for concern over bias.

As for my expertise and professional or comparable qualification I would like to refer to the enclosed CV which demonstrates that I have the skills required for membership in the Supervisory Board of Marinomed Biotech AG.

I herewith declare that

1. I have disclosed all circumstances in connection with Sec. 87 Para. 2 Stock Corporation Act, and that in my fair judgment there are no circumstances that could give cause for concern over bias,
2. I have not been convicted for any criminal act, including without limitation to criminal acts that may call my professional reliability into question according to Sec. 87 Para. 2a 3rd sentence Stock Corporation Act,
3. there are no impediments to my appointment in terms of Sec. 86 Para. 2, including Sec. 86 Para. 2 no. 1 and Sec. 86 Para. 3 Stock Corporation Act (exceeding the statutory maximum limit of supervisory board mandates) and Sec. 86 Para. 4 Stock Corporation Act,
4. I do not hold any corporate roles in other companies that are competing with Marinomed Biotech AG, and
5. I am not in a business or personal relationship with Marinomed Biotech AG or its Management Board that would create a material conflict of interest and would thus be capable of influencing my behaviour as a member of the Supervisory board.

Enclosure:  
Curriculum Vitae

Vienna, May 24, 2023

[Signature]

.....  
Eva HOFSTÄDTER-THALMANN, PhD



**Eva HOFSTÄDTER-THALMANN, PhD**

Having graduated in biochemistry from the University of Vienna, Eva HOFSTÄDTER-THALMANN spent more than 30 years in the pharmaceutical industry, working for Johnson & Johnson and Janssen in several commercial and medical affairs leadership positions. Working in Austria and the USA, her professional responsibilities covered a global perspective including the US and then – over the last 20 years – Europe, the Middle East and Africa. Her tasks extended to the areas of oncology, hematology and virology.

A focal point of her work over the last years included chairing the EFPIA (European Federation of Pharmaceutical Industries and Associations) Working Group on Lifelong Learning in Healthcare, aligning the industry on a quality framework in medical education.

Eva HOFSTÄDTER-THALMANN was a committee member of ESMO's Women4Oncology publishing on the Leadership of Women in Oncology. Currently, she is President of the Global Alliance of Medical Education (GAME) and member of the Board of Directors of the Journal of European Continuing Medical Education (JECME).

Eva HOFSTÄDTER-THALMANN is currently starting an independent consultancy business in healthcare with a focus on strategic stakeholder management, working with the pharmaceutical industry and international medical companies.